Vaccines

Long dismissed as the backwaters of healthcare innovation, the tremendous value of vaccines – the single most cost-effective health intervention after clean water – made itself starkly clear in 2020, as the discovery of a novel coronavirus quickly exploded into a full-blown global pandemic that rages on still.

While billions have since been poured into vaccine development for COVID-19 and vaccine candidates have been developed and approved (albeit so far only for emergency use) at unprecedented speed, sector stakeholders are only cautiously optimistic regarding the longevity of this newly awakened global interest and investment in vaccines – and whether the frenetic zeal to discovering and deploying COVID-19 vaccines would translate into sustained and longer-term efforts to support vaccine R&D for a whole host of other infectious diseases that continue to claim tens of millions of lives annually.

This issue of InFocus dedicated to vaccines features a variety of global, regional and local stakeholders across the public and private spheres to provide a snapshot of the four thematics at the heart of the vaccine sector: Research & Development, Manufacturing & Supply Chain, Partnership Models, and Public Health Impact.

R&D: An Expanded Playbook

The story of how British doctor Edward Jenner serendipitously discovered a way to inoculate people against smallpox in 1976 by injecting them with cowpox pus is well-known. Over the past two centuries, vaccine development platforms have (thankfully) advanced leaps and bounds, delivering a wealth of options to tackle global health challenges.

Business Models & Market Access

While perhaps not as lucrative or – prior to COVID-19 – as attention-grabbing – as other areas of the pharmaceutical industry, vaccines are also not the forgotten backwaters that many industry insiders seem to view them as. While the inherent complexities related to vaccine R&D do impose high barriers to entry and significant costs, new collaboration…

Manufacturing & Supply Chain

Pharma industry insiders view vaccines as one of the most challenging products to manufacture, fundamentally due to the inherent biological variability of the pathogen itself, which is the starting block of any vaccine, as well as the resulting inherent variability of the biological raw materials and processes required in vaccine production. For this reason, the product is very much the process when it comes to vaccine manufacturing. This has also been attributed as one of the main reasons for the relative scarcity of vaccine players globally.

Securing Trust in the COVID-19 Supply Chain: From Development & Delivery to Acceptance & Administration

Scientists have come together in an unparalleled worldwide collaboration and sharing of data to advance a COVID-19 vaccine.[1] As rollouts…

Population Health: Access & AntiVax Challenges

Vaccines have been touted – and rightly so – as the most cost-effective health intervention after access to clean water. It is estimated by global health institutions that vaccines save at least three million lives every year. While tremendous progress has been made since the discovery…

Latest Issue - eBook

Vaccines

Top Story

Exclusive interview with

UNICEF Supply Chain director

Eva Kadilli

“The biggest challenge for us is that while responding to the immediate crisis caused by the global pandemic, we still needed to continue and coordinate our responses to other emergencies”

eBook

Vaccines

Long dismissed as the backwaters of healthcare innovation, the tremendous value of vaccines – the single most cost-effective health intervention after clean water – made itself starkly clear in 2020, as the discovery of a novel coronavirus quickly exploded into a full-blown global pandemic that rages on still.

Top Interviews on PharmaBoardroom

The German Biotech Behind Pfizer’s COVID-19 Vaccine Candidate

German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant Pfizer on a COVID-19 vaccine.

Sustaining the Vaccines Ecosystem Benefits Public Health

Francois Sandre, Head of Asia & JPAC for Sanofi Pasteur outlines the importance of a sustainable global vaccine ecosystem and why a value-based approach…

Top 10 Vaccine Companies Globally

Vaccines are back on top of the pharma priority list as companies race against the clock to develop the first effective COVID-19 vaccine. Below we present the top 10 pharma companies producing vaccines globally…

Canada’s COVID-19 Vaccination Strategy - Fasken Canada (Dec 2020)

Vaccination is a historically successful strategy to prevent the spread of infectious diseases. The immunization of a large enough proportion of a population will reduce the percentage of…

Ebola Vaccine Lessons for COVID-19 & The Future of Global Health

Epidemiologist John-Arne Røttingen has had a long and distinguished career in both academia and industry, including stints at Oslo, Oxford and Harvard universities, as well as helping…

Discover our country reports

Previous
Next

PharmaBoardroom

Contact us

+44 20 7867 3717 info@pharmaboardroom.com

For media inquiries, please contact: media@pharmaboardroom.com

Address

PharmaBoardroom Limited Lynton House, 7-12, Tavistock Square, London, United Kingdom, WC1H 9LT

Subscribe